● Recruiting

A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

Condition: Glioblastoma · Recurrent Glioblastoma · Brain Tumor · Sponsor: Ugonma Chukwueke

PhaseEARLY_Phase 1

Planned participants27

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This research study is studying troriluzole as a possible treatment for recurrent glioblastoma. The name of the study drug involved in this research study is: -Troriluzole (a tripeptide prodrug of riluzole)

This description comes directly from the study's public registry record.

Talk to the study team

Ugonma Chukwueke, MD · 617-632-2166 · Ugonma_Chukwueke@DFCI.HARVARD.EDU

Always discuss trial participation with your own doctor first.

Locations (3)

Brigham and Women's Hospital	Boston, Massachusetts, United States	Recruiting
Dana-Farber Cancer Institute	Boston, Massachusetts, United States	Recruiting
Massachusetts General Hospital Cancer Center	Boston, Massachusetts, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06552260